251643-13-7

Basic information

• Product Name: Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI)
• Synonyms: Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI);5-(Methoxycarbonyl)-N-methyl-2-nitroaniline, 4-(Methoxycarbonyl)-2-(methylamino)nitrobenzene
• CAS NO: 251643-13-7
• Molecular Formula: C₉H₁₀N₂O₄
• Molecular Weight: 210.1867
• Product Categories: AMINOACID
• Mol File: 251643-13-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 386.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.325±0.06 g/cm3(Predicted)
• PKA: -1.28±0.25(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI)(251643-13-7)
• EPA Substance Registry System: Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI)(251643-13-7)

Safety Data

• Hazardous Substances Data: 251643-13-7(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI) is a chemical compound with the molecular formula C9H9NO4. It is a methyl ester derivative of 3-(methylamino)-4-nitrobenzoic acid, commonly known as MNB. Benzoic acid, 3-(methylamino)-4-nitro-, methyl ester (9CI) is a yellow crystalline powder that is soluble in organic solvents and insoluble in water. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Additionally, it has been studied for its potential applications in the treatment of neurological disorders and cancer. However, it is important to note that this compound is classified as hazardous, and proper safety precautions should be followed when handling it.

Upstream product

• 76143-33-4 5-(methoxycarbonyl)-2-nitrobenzoic acid 
• 99512-09-1 3-amino-4-nitrobenzoic acid methyl ester 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 

Downstream Products

• 251643-08-0 3-[N-Methyl-N-(tert-butyloxycarbonyl)amino]-4-nitrobenzyl alcohol 
• 251643-15-9 3-[N-Methyl-N-(tert-butyloxycarbonyl)amino]-4-nitrobenzoic acid 
• 251643-32-0 Methyl 4-(N-methyl-N-{3-[N-methyl-N-(tert-butyloxycarbonyl)amino]-4-nitrobenzyloxycarbonyl}amino)phenylacetate 
• 251643-41-1 4-(N-Methyl-N-{3-[N-methyl-N-(tert-butyloxycarbonyl)amino]-4-nitrobenzyloxycarbonyl}amino)phenylacetic acid 
• 251643-51-3 N-[2-(N,N-Dimethylamino)ethyl] 4-(N-methyl-N-{3-[N-methyl-N-(tert-butoxycarbonyl)amino]-4-nitrobenzyloxycarbonyl}amino)phenylacetamide 
• 53484-18-7 1-methyl-6-benzimidazole carboxylic acid 
• 1038387-93-7 methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate 
• 131020-50-3 methyl 1-methyl-1H-benzo[d]imidazole-6-carboxylate 
• 863564-77-6 3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylic acid 
• 616224-38-5 methyl 4-amino-3-(methylamino)benzoate 
• 251643-14-8 Methyl 3-[N-methyl-N-(tert-butyloxycarbonyl)amino]-4-nitrobenzoate 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

GLP-1 Receptor Agonists and Uses Thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.